2. Правовая и методическая основа
Федеральный закон Российской Федерации от 12 апреля 2010 г. №61-ФЗ «Об обращении лекарственных
средств»
Statistical Approaches to Establishing Bioequivalence (FDA 2001)
L.X. Yu and B.V. Li (eds.), (2014) FDA Bioequivalence Standards, AAPS Advances in the Pharmaceutical Sciences.
Series 13, Springer, New York
Hauschke,Dieter.Bioequivalencestudiesindrug development : methods and applications / Dieter Hauschke, Volker
Steinijans, Iris Pigeot. p. ; cm. John Wiley & Sons Ltd. 2007
Shein-ChungChow,Jen-peiLiu.DesignandAnalysis of Bioavailability and Bioequivalence Studies, 3d Ed. Taylor &
Francis Group, LLC. 2009
Davit BM, Conner DP, Fabian-Fritsch B et al (2008) Highly variable drugs: observations from bioequivalence data
submitted to the FDA for new generic drug applications. AAPS J 10:148–156
Benet L (2004) Why highly variable drugs are safer, FDA Advisory Committee for Pharmaceu- tical Sciences and
Clinical Pharmacology meeting transcript. Available via US Food and Drug Administration Dockets.
http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4034T2.htm. Accessed 19 Feb 2014